Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.54 |
| ▸ | SLC18A2 | Q05940 | 5/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10323210 | 0.99 | HTR2A (0.53) | HTR2ASLC18A2SLC6A3ALDH1A1CYP3A4 | |
| SCHEMBL342659 | 0.87 | HTR2A (0.53) | HTR2AKCNH2HTR1ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL10322898 | 0.86 | HTR2A (0.52) | HTR2AKCNH2HTR1ADRD2DRD3 | |
| SCHEMBL341319 | 0.85 | SLC18A2 (0.54) | HTR2ASLC18A2SLC6A3ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL10321482 | 0.84 | SLC18A2 (0.54) | HTR2ASLC18A2SLC6A3ALDH1A1CYP3A4 | |
| SCHEMBL6329094 | 0.81 | HTR2A (0.53) | HTR2AOPRM1TMEM97 | |
| SCHEMBL339810 | 0.80 | HTR2A (0.58) | HTR2AOPRM1TMEM97 | |
| Hydrochloric Acid SCHEMBL10321804 | 0.79 | HTR2A (0.57) | HTR2AOPRM1TMEM97 | |
| SCHEMBL342383 | 0.79 | HTR2A (0.79) | HTR2A | |
| SCHEMBL341115 | 0.79 | HTR2A (0.61) | HTR2AOPRM1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538222-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20060205722-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2006-09-14 | — | — | US | claimed |
| US-20060199818-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | claimed |
| US-20060094758-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | claimed |
| EP-1562937-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | Acadia Pharmaceuticals Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | claimed |
| WO-2004000808-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097625-B2 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | SUNOVION PHARMACEUTICALS INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7538222-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7476682-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060094758-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| EP-1562937-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | Acadia Pharmaceuticals Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | SEPRACOR, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004000808-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | HTR2A, HTR2C, HTR5A | HTR2A 1/4885SLC18A2 29/4885SLC6A3 35/4885 |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | HTR2A 12/4885SLC18A2 8/4885SLC6A3 20/4885 |
| US-20060094758-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | HTR2A 10/4885SLC18A2 13/4885SLC6A3 21/4885 |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | HTR4, HTR3B, HTR2A | HTR2A 3/4885SLC18A2 80/4885SLC6A3 233/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | HTR2A 1/4885SLC18A2 64/4885SLC6A3 69/4885 |
| US-20060205722-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | HTR2A 10/4885SLC18A2 13/4885SLC6A3 21/4885 |
| US-20060199818-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | HTR2A 10/4885SLC18A2 13/4885SLC6A3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.